Physician profile
Jad A Khoury
NPI 1144250028
$2,522.42
in general payments reported to CMS, 2019-2025
19 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $111 · 2021: $130 · 2022: $335 · 2023: $453 · 2024: $273 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $789.12 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $303.56 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Abbvie INC. | $298.81 | 2019-2025 | |
| Insmed, INC. | $270.89 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $216.66 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Shionogi INC | $148.68 | 2020-2025 | Fetroja |
| Janssen Biotech, INC. | $92.54 | 2019-2023 | Symtuza |
| Astellas Pharma US INC | $65.63 | 2019-2022 | |
| Allergan, INC. | $57.18 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $44.50 | 2024-2025 | Vowst |
| La Jolla Pharmaceutical Company | $37.05 | 2024-2025 | Zevtera, Xacduro |
| Cumberland Pharmaceuticals, INC. | $35.82 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $33.32 | 2019 | |
| Pfizer INC. | $32.99 | 2022-2025 | |
| Melinta Therapeutics, LLC | $27.67 | 2021-2024 | Kimyrsa, Rezzayo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $19.44 | 2022 | |
| Emd Serono, INC. | $17.99 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.51 | 2025 | Nuzyra |
| Nabriva Therapeutics, Plc | $15.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jad Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.